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Alterations of p75 neurotrophin receptor and Myelin transcription factor 1 in the
hippocampus of perinatal phencyclidine treated rats
Abstract
Postnatal administration of phencyclidine (PCP) in rodents causes major disturbances to neurological
processes resulting in severe modifications to normal behavioral traits into adulthood. It is routinely used
to model psychiatric disorders such as schizophrenia, producing many of the dysfunctional processes in
the brain that are present in this devastating disorder, including elevated levels of apoptosis during
neurodevelopment and disruptions to myelin and plasticity processes. Lingo-1 (or Leucine-rich repeat and
immunoglobulin domain-containing protein) is responsible for negatively regulating neurite outgrowth and
the myelination of axons. Recent findings using a postmortem human brain cohort showed that Lingo-1
signaling partners in the Nogo receptor (NgR)/p75/TNF receptor orphan Y (TROY) signaling complex, and
downstream signaling partners With No Lysine (K) (WNK1) and Myelin transcription factor 1 (Myt1), play a
significant part in schizophrenia pathophysiology. Here we have examined the implication of Lingo-1 and
its signaling partners in a neurodevelopmental model of schizophrenia using PCP to determine if these
pathways are altered in the hippocampus throughout different stages of neurodevelopment. Male
Sprague-Dawley rats were injected subcutaneously with PCP (10 mg/kg) or saline solution on postnatal
days (PN) 7, 9, and 11. Rats (n = 6/group) were sacrificed at PN12, 5 weeks, or 14 weeks. Relative
expression levels of Lingo-1 signaling proteins were examined in the hippocampus of the treated rats.
p75 and Myt1 were decreased (0.001 ≤ p ≤ 0.011) in the PCP treated rats at PN12. There were no
significant changes in any of the tested proteins at 5 weeks (p > 0.05). At 14 weeks, p75, TROY, and Myt1
were increased in the PCP treated rats (0.014 ≤ p ≤ 0.022). This is the first report of an alteration in
Lingo-1 signaling proteins in the rat hippocampus, both directly after PCP treatment in early development
and in adulthood. Based on our results, we propose that components of the Lingo-1 signaling pathways
may be involved in the acute neurotoxicity induced by perinatal administration of PCP in rats early in
development and suggest that this may have implications for the hippocampal deficits seen in
schizophrenia.
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Abstract
Postnatal administration of phencyclidine (PCP) in rodents causes major disturbances to
neurological processes resulting in severe modifications to normal behavioural traits into
adulthood. It is routinely used to model psychiatric disorders such as schizophrenia,
producing many of the dysfunctional processes in the brain that are present in this devastating
disorder; including elevated levels of apoptosis during neurodevelopment, and disruptions to
myelin and plasticity processes. Lingo-1 (or Leucine-rich repeat and immunoglobulin
domain-containing protein), is responsible for negatively regulating neurite outgrowth and
the myelination of axons. Recent findings using a postmortem human brain cohort showed
that Lingo-1 signaling partners in the Nogo receptor (NgR)/p75/TNF receptor orphan Y
(TROY) signaling complex, and downstream signaling partners With No Lysine (K) (WNK1)
and Myelin transcription factor 1 (Myt1), play a significant part in schizophrenia
pathophysiology. Here we have examined the implication of Lingo-1 and its signaling
partners in a neurodevelopmental model of schizophrenia using PCP to determine if these
pathways are altered in the hippocampus throughout different stages of neurodevelopment.
Male Sprague Dawley rats were injected subcutaneously with PCP (10mg/kg) or saline
solution on postnatal days (PN)7, 9 and 11. Rats (n=6/group) were sacrificed at PN12, 5
weeks or 14 weeks. Relative expression levels of Lingo-1 signaling proteins were examined
in the hippocampus of the treated rats. p75 and Myt1 were decreased (0.001≤p≤0.011) in the
PCP treated rats at PN12. There were no significant changes in any of the tested proteins at 5
weeks (p>0.05). At 14 weeks, p75, TROY, and Myt1 were increased in the PCP treated rats
(0.014≤p≤0.022). This is the first report of an alteration in Lingo-1 signaling proteins in the
rat hippocampus; both directly after PCP treatment in early development, and in adulthood.
Based on our results we propose that components of the Lingo-1 signaling pathways may be
involved in the acute neurotoxicity induced by perinatal administration of PCP in rats early in
development and suggest that this may have implications for the hippocampal deficits seen in
schizophrenia.

Keywords: schizophrenia; Lingo-1 signaling; neurodevelopment; phencyclidine animal
model; hippocampus
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1. Introduction
Phencyclidine, also known as angel dust or PCP, is both a potent non-competitive N-methylD-aspartate (NMDA) receptor antagonist and an agonist for the dopamine D2 receptors1–3,
but also binds with a lower affinity to opiate, nicotinic, and muscarinic cholinergic
receptors4–7. Due to its effects on a multitude of important receptor targets known to be
implicated in the schizophrenia pathology, PCP treatment in rodents has been used to model
the glutamate hypofunction hypotheses and dopamine hyperfunction hypotheses of
schizophrenia2,8. The use of PCP administration at postnatal days (PN)7, 9 and 11 has
consistently been shown to induce hyperlocomotion, reduced prepulse inhibition and
impaired social interactions in rodents9–11. The behaviors it induces in rodents in addition to
the psychomimetic effects it has in humans, makes it a valid model for studying the
development of schizophrenia12.
The administration of PCP to rodents both induces neurotoxicity and causes major damage to
all parts of the brain13,14. PCP administration at PN7, 9 and 11 has been repeatedly shown to
result in an increase in neuronal degeneration in the frontal and cingulate cortex of rats15,16.
Similarly, pro-apoptotic factors have been shown to be upregulated, and anti-apoptotic
factors have been shown to be downregulated in rats treated perinatally with PCP compared
to controls15. It is thought that elevated neuronal death during this perinatal period may be
directly responsible for deficits in brain development, neuronal cytoarchitecture and
plasticity; and thus may contribute to the appearance of some of the schizophrenia-like
symptoms seen in these rats in adulthood. Furthermore, neurons are not the only brain cells
that are affected by disruptions to NMDA receptor antagonists. Oligodendrocytes, like
neurons are sensitive to PCP toxicity during development14, and considering their significant
role in axonal connectivity and conduction, disruption to these processes during early
neurodevelopment can have significant negative consequences, impacting on normal brain
3

development. Furthermore, oligodendrocytes play a major role in myelination processes,
which have been shown to be altered after PCP treatment in rats13,14. We have previously
shown in this rat model that myelin basic protein (MBP), a marker of mature
oligodendrocytes is significantly reduced in early development by perinatal administration of
PCP17.
Here we study the effects of PCP treatment on Leucine-rich repeat and immunoglobulin
domain-containing protein (Lingo-1) pathways, which are highly involved the regulation of
myelination and neurite outgrowth processes, both integral processes involved in the
pathophysiology of schizophrenia. Membrane bound signal-transducing protein Lingo-1 is
expressed on both neurons and oligodendrocytes18. It signals alongside the Nogo receptor
(NgR) co-receptor and either the p75 neurotrophin receptor or its functional homolog, TNF
receptor orphan Y (TROY)19–21, both of which also play significant roles in apoptosis and cell
survival pathways22,23. Altogether, the activation of this trimolecular receptor complex sets up
a signaling cascade leading to growth cone collapse, preventing further axonal growth and
inhibiting myelination18,24. Additional signaling co-factors such as With No Lysine K
(WNK1)25, Myelin transcription factor 1 (Myt1) and its homolog Myt1-like (Myt1l) are
known to be associated with Lingo-1 signaling due to a lack of p75 and TROY receptors on
Lingo-1 expressing neurons26,27. Genetic associations with schizophrenia have been
previously reported for the Myt1l gene in different populations28,29, and the knockdown of
Myt1 has been shown to induce apoptosis30, strengthening the relevance of studying this
Lingo-1 cofactor in a neurodevelopmental PCP induced model for schizophrenia.
We have recently reported the first evidence of an alteration in Lingo-1 signaling pathways in
a postmortem hippocampal human brain cohort for schizophrenia31. Considering the role of
Lingo-1 signaling proteins in myelin related processes, the present study specifically focuses
on Lingo-1 signaling protein alterations in the hippocampus due to activity-mediated myelin
4

growth being higher early in human life in hippocampal regions compared to cortical
regions32. Considering that the perinatal administration of PCP to rodents is a wellestablished developmental animal model for schizophrenia, we sought to investigate the
effects of developmental PCP administration on levels of expression of Lingo-1 signaling
proteins in the hippocampus, a critical region for early brain development.
2. Methods
2.1 Animals
Timed pregnant Sprague Dawley rats were obtained at gestation day 14 from the Animal
Resource Centre (Perth, WA, Australia). Rats were housed in environmentally controlled
conditions at 22°C in a 12 hours on, 12 hours off light dark cycle with food and water access
ad libitum. The day of birth was denoted postnatal day (PN)0, and the pups were sexed on
PN7 when the litters were subsequently randomly assigned to PCP or saline groups. The
female pups remained in the litters until weaning, however only male rats were used in this
study. The pups were weaned at PN24-28, and were housed in pairs according to treatment.
This study was approved by the Animal Ethics Committee at The University of Wollongong
(AE13/01), and was conducted according to the guidelines of the Australian code of Practice
for the Care and Use of Animals for Scientific Purposes, conforming to the International
Guiding Principles for Biomedical Research Involving Animals. All efforts were made to
minimize numbers of animals used and their suffering.
2.2 Perinatal PCP Treatment
Male Sprague Dawley rat pups were given a subcutaneous injection on PN7, 9 and 11; of
PCP (10 mg/kg/day; Sigma, Castle Hill, NSW, Australia) or saline (0.9% NaCl at a volume
of 1 ml/kg). Six rats from each treatment group (PCP and control) were sacrificed at three
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different time-points, PN12 days, 5 weeks or 14 weeks of age, representing perinatal,
adolescent and adult developmental stages respectively as described previously33,34.
2.3 Rat Brain Tissue Preparation
Rats were euthanized by carbon dioxide asphyxiation and decapitation at PN12, 5 weeks and
14 weeks. Brains were extracted and the hippocampus was regionally dissected on ice with
the aid of a standard rat brain atlas35. Immediately following dissection samples were snap
frozen in liquid nitrogen and then stored at -80°C. Tissue was gently homogenized in a buffer
(50 mM Tris pH 7.5, 50% glycerol), containing protease inhibitors (Sigma). Protein
concentrations were determined by a spectrophotometer. All samples were diluted to a
concentration of 2 μg/μL and stored at -80°C until required for immunoblotting, as previously
detailed31.
2.4 Immunoblotting
Relative protein levels for all proteins of interest were determined by immunoblotting as
previously described31. In short, proteins were resolved by SDS-PAGE, with a total of 10 µg
protein loaded into each well of 4-12% pre-cast bis-Tris polyacrylamide gels (Bio-Rad).
Proteins were subsequently transferred to polyvinylidene fluoride membranes (Bio-Rad). The
polycolonal and monoclonal antibodies and their respective concentrations used to probe the
membranes were as follows: anti-Lingo-1 (1:500; ab23631 Abcam), anti-NgR (1:500;
ab26291 Abcam), anti-p75 (1:500; ab8874 Abcam), anti-TROY (1:200; ab12126 Abcam),
anti-WNK1 (1:500; ab128858 Abcam), and anti-Myt1 (1:500; ab82844 Abcam). The Gel
Logic 2200 Pro (Carestream Molecular Imaging; Rochester, NY, USA) was used to visualize
and quantify the bands of interest. All samples were run in duplicate or triplicate, and were
loaded in a randomized order with even numbers of PCP and control samples per time-point
per gel to minimize the effects of gel-to-gel variability on the results. A pooled sample
6

combining aliquots from all 36 rats, was used as a positive control and was loaded onto each
gel within the experiment to account for any gel-to-gel variability. Samples from each gel
were then normalized to their respective pooled sample, and all bands were normalized to a
β-actin (1:5000; MAB1501 Millipore) same lane loading control. Mean β-actin expression
levels did not differ between PCP and control groups (p>0.05). All experiments and
quantifications were performed blind to treatment and age group.
2.5 Statistics
As all data were normally distributed (Kolmogorov–Smirnov p>0.10), parametric testing was
implemented. Two-way multivariate analyses of variance (MANOVA) followed by Tukey’s
HSD post-hoc tests, were performed to assess interactions between treatment (PCP or
control) and time-point (PN12, 5 weeks or 14 weeks). One-way analyses of variance
(ANOVA) followed by Tukey’s HSD post-hoc tests, were used to assess for differences in
protein expression across successive developmental time points within each treatment group.
Unpaired two-tailed t-tests were also used at individual time-points to assess for differences
in protein expression between PCP and control groups. The significance for all statistical tests
was set to p<0.05. All data are expressed as mean±SD.
3. Results
3.1 Protein detection
Lingo-1, NgR, p75, TROY, WNK1 and Myt1 proteins were abundantly expressed and
detectable in the rat hippocampus. Western blot analyses of all proteins examined resulted in
a single distinct band at the expected, previously reported molecular weights for each protein:
Lingo-1 (83 kDa)36, NgR (51 kDa)37, p75 (75 kDa)38, TROY (46 kDa)39, WNK1 (250 kDa)31,
and Myt1 (135 kDa)31 (Figure 1).
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3.2 Hippocampal levels of p75, TROY and Myt1 protein expression are altered by
perinatal administration of PCP in rats
There was a highly significant age x treatment interaction on levels of both p75 and TROY
protein expression in the treated rats (F2,30=9.39; p<0.001; and F2,30=7.69; p=0.002
respectively). Post-hoc analyses reveal that at PN12, a significant decrease in p75 protein
expression (-16%, p=0.011; Figure 1) was observed in perinatal PCP treated rats in
comparison to control rats. Despite a decrease in levels of TROY, the functional homolog of
p75, it was found not to be significantly different in PCP treated versus control rats at the
PN12 time-point (-11%, p=0.061; Figure 1). Furthermore, a significant elevation in p75
protein expression was observed in PCP treated compared to control rats at the 14 week timepoint (+22%, p=0.022; Figure 1). Similarly, levels of the p75 homolog TROY were also
found to be significantly elevated in PCP treated compared to control rats at the 14 week
time-point (+14.5%, p=0.021; Figure 1). While there was no considerable main effect of
treatment on expression levels of p75 or its homolog TROY (F1,30=0.23; p=0.633; and
F1,30=0.15; p=0.705 respectively), an extremely significant age effect on both p75 and TROY
expression levels in the hippocampus of the treated rats was observed (F2,30=26.95; p<0.001;
and F2,30=34.27; p<0.001 respectively; Supplementary Figures (SF) 1 and 2). Post-hoc
analyses revealed that the age effect resulted in a significant increase in p75 (control: +25%,
p=0.001, SF1; PCP: +47.5%, p<0.001, SF2) and TROY (control: +22.5%, p<0.001, SF1;
PCP: +36%, p<0.001, SF2) when comparing the 5 week age groups to the PN12 age group.
Furthermore, a significant elevation in both p75 (+49%, p<0.001, SF2) and TROY (+37%,
p<0.001, SF2) expression was observed in the 14 week PCP treated rats compared to the
PN12 PCP treated rats, however there was no significant alteration observed in the control
rats when comparing the same age groups (SF1). Finally, there was a significant increase in
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both p75 (+22%, p=0.008, SF1) and TROY (+15%, p=0.037, SF1) protein expression in
control rats when comparing the 5 week to the 14 week group.
Similar to the results of p75 and TROY, there was an extremely significant interaction
between age and treatment on Myt1 levels in the hippocampus of the treated rats
(F2,30=25.52; p<0.001). Post-hoc testing revealed that this interaction again results in a
decrease at the PN12 (-18.5%, p<0.001; Figure 1) and an increase at the 14 week (+16%,
p=0.014; Figure 1) time-points between the PCP treated rats and the controls. Furthermore,
while there is no main treatment effect (F1,30=0.96; p=0.333), there was a considerable age
effect on levels of Myt1 protein expression (F2,30=103.13; p<0.001). Post-hoc analyses
showed that Myt1 was significantly altered when comparing the 5 week group to the PN12
group (control: -15.5%, p=0.001, SF1; PCP +9%, p=0.016, SF2), when comparing the 14
week group to the 5 week group (control: -43.5%, p<0.001, SF1; PCP -30%, p<0.001, SF2),
as well as when comparing the 14 week group to the PN12 group (control: -69%, p<0.001,
SF1; PCP -16%, p=0.001, SF2).
3.3 Hippocampal levels of Lingo-1, NgR and WNK1 protein expression are unaltered by
perinatal PCP treatment in rats
There were no significant main effects of age (F2,30=3.01; p=0.064) or treatment (F1,30=0.36;
p=0.555) on levels of Lingo-1 in the hippocampus of the treated rats; nor were there any
significant interactions between the two factors (F2,30=1.41; p=0.259; Figure 1). Furthermore
there were no significant interactions between age and treatment on levels of NgR in the
treated rats (F2,30=0.54; p=0.589; Figure 1), nor an effect of treatment on NgR levels in the
hippocampus (F1,30=0.14; p=0.710). However, an extremely significant age effect was
observed in relation to NgR protein levels in the hippocampus of the treated rats (F2,30=18.69;
p<0.001). Post-hoc analyses demonstrated that this age effect resulted in a considerable
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increase in NgR expression levels in both control and PCP treated rats in both the 5 week
(control: +55%, p=0.002, SF1; PCP: +48%, p=0.001, SF2) and 14 week (control: +37%,
p=0.019, SF1; PCP: +49%, p=0.005, SF2) age groups compared to the PN12 age group, with
the age effect being more highly significant in the PCP treated rats.
As with Lingo-1 and NgR, there were no notable age x treatment interactions on the
expression of hippocampal WNK1 protein levels in the treated rats (F2,30=0.39; p=0.683;
Figure 1), nor an effect of treatment on WNK1 levels in the treated rats (F1,30=0.24; p=0.627).
There was however a considerable age effect on WNK1 protein expression levels
(F2,30=12.60; p<0.001). Similar to the expression pattern of NgR, post-hoc analyses revealed
that the age effect resulted in a significant elevation of WNK1 expression levels in both
control and PCP treated rats in both the 5 week (control: +29.5%, p=0.007, SF1; PCP:
+46.5%, p=0.003, SF2) and 14 week (control: +34.5%, p=0.014, SF1; PCP: +49%, p=0.003,
SF2) age groups compared to the PN12 age group, with the age effect again being more
highly significant in the PCP treated rats.
4. Discussion
Here we provide the first study to investigate the developmental expression profile of
hippocampal Lingo-1 signaling pathway proteins using a neurodevelopmental PCP model of
schizophrenia. This study offers insight into the expression patterns of these proteins
following the administration of an NMDA receptor antagonist at a critical period for brain
development which is highly relevant in the context of the pathophysiology of schizophrenia.
We have shown that the hippocampal expression of Lingo-1, NgR and WNK1 were not
significantly altered by PCP treatment across the 3 tested developmental time-points,
however the downstream signaling partners p75, TROY and Myt1 were decreased at PN12
and increased at 14 weeks in PCP treated rats compared to their controls. Considering current
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literature and the role that these three proteins play in apoptotic processes, our results suggest
that these proteins may have implications in acute PCP induced neurotoxicity and thus may
contribute to deficits in brain development, neuronal cytoarchitecture and plasticity of the
brain early in the development of schizophrenia.
4.1 Alterations of p75, TROY and Myt1 in a PCP induced neurodevelopmental animal
model for schizophrenia
Perinatal PCP treatment was found to significantly reduce p75 expression in the juvenile rats,
and increase the expression of p75 in the adult PCP treated rats, with no change in p75
expression in the adolescent rats (Figure 1). Reports on the expression of p75 neurotrophin
receptor throughout development as well as in relation to schizophrenia in human
postmortem brains, are limited and conflicting40, despite the p75 binding protein, brainderived neurotrophic factor (BDNF) being extensively studied41–43. In support of our
findings, levels of p75 expression have been previously found to be significantly reduced in
neonatal pups in a developmental rodent model used to study environmental influences in
disorders such as schizophrenia44. It has been suggested that a reduction of p75 in early brain
development could be quite detrimental due to the inability for neurotrophins, responsible for
neurite outgrowth, to bind in a p75 dependent fashion, leading to an inability of axons to
elongate throughout development45. Even though p75 expression is known to be associated
with various apoptotic processes46,47, p75 neurotrophic factor also contributes to neuronal
survival during development40,46. Tropomyosin receptor kinases (Trk), involved in p75induced neuronal survival processes40, are also implicated in NMDA receptor activation and
regulation41. With regards to the non-specific antagonistic effects of PCP on the NMDA
receptor, a decrease in the activity of TrkB receptor signaling has been shown in postnatal
PCP treated rats48 (Figure 2). Due to the cross talk between p75 and Trk receptors, it was not
surprising to see a significant reduction in the levels of p75 in the hippocampus of the
11

juvenile PCP treated rats compared to the controls in our study, which would lead to
decreased survival of neurons early in development. As a follow-up to our study and to test
this hypothesis, the levels of microtubule-associated protein 2 (MAP2; a commonly used
neuronal marker, selectively labeling dendritic trees throughout the brain) were examined in
the hippocampus of our perinatal treated rats (see supplementary methods, results and figure
SF3). MAP2 levels were significantly decreased by 26.5% in the hippocampus of the juvenile
PCP treated rats (p=0.008), supporting our hypothesis that a significant reduction in p75 in
PCP treated rats would lead to an acute reduction in survival of neurons in the hippocampus
of juvenile treated rats.
Considering that p75 and TROY are functional homologs of one another, it seems fitting that
we found a decrease of a similar magnitude in both p75 and TROY expression in the
hippocampus of perinatal PCP treated rats, despite the reduction in TROY protein levels not
reaching significance (p=0.061). We suggest that the very similar transient expression pattern
of the homologous receptors p75 and TROY in PCP treated rats compared to controls
throughout development may play a significant role in PCP induced neurotoxicity in juvenile
rats in our neurodevelopmental animal model of schizophrenia. In support of this, it has been
shown that postnatal PCP injections resulted in lower levels of phosphorylated ERK1/2 in the
hippocampus of juvenile rats compared to controls49,50. Furthermore PCP treatment in
organotypic brain slice culture from rats showed decreased phosphorylation levels of
MEK1/2 and ERK1/2, both downstream signaling partners of p75 cell survival pathways,
suggesting that PCP may induce cell death through the inhibition of the MEK/ERK/1/2 prosurvival pathways51 (Figure 2). The expression pattern of p75 and TROY seems to recover
over time, normalizing around adolescence as there are no significant differences in either
p75 or TROY expression in the 5 week old rats (p>0.05). Furthermore, there are no
significant alterations in MAP2 levels to indicate any significant alterations in neuronal
12

survival during adolescence (SF3). The levels of p75 and TROY are raised above control
levels in the hippocampus of PCP treated rats by the time they reach adulthood at 14 weeks.
This is supported by our previous finding in a postmortem human cohort showing an increase
of both of these proteins in the hippocampus of adult schizophrenia brains compared to
controls, despite p75 levels not reaching significance in our human study31. Considering there
are no significant alterations in MAP2 levels between PCP treated and control rats at
adulthood in the present study (SF3), this suggests that additional mechanisms may be
involved in the regulation of these proteins in the adult schizophrenia brain which will need
to be further investigated.
In addition, Myt1 expression in our study was found to be significantly decreased by PCP
administration in the hippocampus of the juvenile PN12 rats in comparison to control rats,
but increased in the adult rats treated perinatally with PCP compared to controls. Knowing
that Lingo-1 can directly suppress EGFR signaling leading to the inhibition and blockade of
PI3-K/Akt signaling pathways31, and since we found Lingo-1 to be unaltered in the
hippocampus in the perinatal PN12 PCP treated rats in the present study, we hypothesize that
Akt signaling pathway inhibition by Lingo-1 would be reduced, thus resulting in increased
levels of phosphorylated Akt signaling pathway proteins (Figure 2). Elevated Akt activation
levels would lead to increased negative regulation of Myt1 intracellularly (Figure 2), thus
resulting in lower Myt1 levels in the hippocampus of the juvenile PCP treated rats31. While
we were unable to examine levels of phosphorylated Akt levels to support this hypothesis in
the present study (due to an alternate method of sample preparation being required for the
procedure), we were able to examine levels of total Akt protein (see supplementary methods,
results and figure SF3). We found that there were no significant alterations in total Akt levels
in any of the tested age groups in PCP rats compared to controls (p>0.05). This result has
been previously shown by our research group34; furthermore in the same cohort of rats our
13

group has demonstrated that perinatal PCP treatment at PN7, 9 and 11 results in increased
levels of phosphorylated Akt at both juvenile and adolescent stages of life in the
hippocampus34, supporting our hypothesis for increased levels of activated Akt in this model
leading to the reduced levels of Myt1 protein observed in juvenile rats in the present study. In
further support of this, Xia and Johnson (2009) have also demonstrated that phosphorylated
Akt levels were increased in adolescent rats that were treated with PCP on postnatal days 7, 9
and 11 compared to rats treated with saline49,50. Along with the decreased levels of Myt1
protein in PCP treated rats at the juvenile period compared to their controls, we have reported
in a previous study17 the levels of MBP as a marker of mature oligodendrocytes in this animal
model, and have shown that MBP is significantly reduced in PN12 animals following
perinatal PCP administration, suggesting an acute alteration of glia by PCP treatment.
In addition, elevated levels of activated Akt may contribute to an increased expression of the
apoptotic marker p53, responsible for regulating another apoptotic marker bcl-2-associated X
protein (or BAX) which has previously been reported to be increased after PCP
administration at PN7, 9 and 1152. To test this hypothesis as a follow-up to our study, we
examined levels of BAX protein in our rats (see supplementary methods, results and figure
SF3) and found a significant 26% increase in BAX expression in the juvenile PCP treated rats
compared to controls (p=0.03). Since p53 and BAX are regulated by Mouse double minute 2
homolog (MDM2)53,54, we would also expect to see an increase in MDM2 expression in the
juvenile rats due to a rise in the levels of p53 and following perinatal PCP administration
requiring a large recruitment of MDM2 for its ubiquitination (Figure 2).
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4.2 Hippocampal expression of Lingo-1 and its signaling proteins NgR, and WNK1 are
unaltered following perinatal PCP treatment
Hippocampal levels of Lingo-1 and NgR both presented with similar transient expression
patterns throughout development in both the control and PCP treated rats, despite neither of
the proteins being significantly altered by PCP treatment at any of the three developmental
time-points (Figure 1); both proteins were increased during adolescence (SF1 and SF2).
Considering the extensive synaptic changes that occur during adolescence (reductions in
dendritic arborization, and pruning of synapses)55, it was not surprising to detect higher levels
of these important negative regulators of neurite outgrowth at this critical period of
development in the control rats. Although slightly reduced following PCP treatment, levels of
both proteins were still elevated in the adolescent rats above that which is seen in the juvenile
rats, and remained elevated into adulthood (SF2).
Similarly, levels of WNK1 expression were gradually increased with age in the hippocampus
of both the control and PCP treated rats. Our finding is consistent with a recent observation
demonstrating elevated WNK1 expression in the hippocampus of adult compared to juvenile
PN10 mouse brains56. Furthermore, WNK1 levels were also found to be unaltered in all age
groups of the present study when comparing PCP treated rats to control rats; similar to the
expression patterns of Lingo-1 and NgR in this study. Considering that WNK1 is a direct
binding partner of Lingo-1 and since WNK1 directly regulates NgR31, it seems appropriate
that we observed these similar profiles of expression for Lingo-1, NgR and WNK1 following
the perinatal PCP treatment.
5. Conclusion
In review, we report for the first time alterations in Lingo-1 signaling pathway proteins,
particularly those which have significant roles in neuronal survival and apoptotic processes,
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in the hippocampus of rats from a neurodevelopmental PCP model of schizophrenia. We have
shown an altered developmental trajectory of a number of these signaling proteins, in
particular at perinatal and adult stages of life. Our results in concert with current literature,
suggest that components of the Lingo-1 signaling pathways may be involved in the acute
neurotoxicity induced by perinatal administration of PCP in rats and suggest that this may
have implications for the hippocampal deficits seen in schizophrenia, however further studies
will be required to fully elucidate the molecular mechanisms involved.
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Figure Legends
Figure 1: Relative levels of protein expression in the hippocampus of phencyclidine (PCP)
treated rats compared to controls (n=6 per treatment per time-point). * p<0.05, ** p<0.01
and *** p<0.001.
Figure 2: Proposed schematic representation of the acute effects of phencyclidine (PCP)
administration resulting in activation of cell death pathways. A reduction in p75 protein
expression was observed in the present study, and TrkB receptor signaling activity has
previously been shown to be reduced in postnatal PCP treated rats. Together these proteins
are normally involved in p75-induced neuronal survival processes1; a reduction in protein or
phosphorylation levels can lead to a reduction in MEK1/2 and ERK1/2 activation. Reduced
phosphorylation of the MEK1/2 ERK1/2 pathways has been shown to result from PCP
treatment2. Lingo-1 can directly inhibit EGFR leading to the inhibition of PI3-K/Akt
signaling pathways3; since Lingo-1 was unaltered in the present study, we suggest that Lingo1 induced inhibition of Akt signaling pathways would be reduced and result in increased Akt
signaling, causing increased negative regulation of Myt1 intracellularly3. Our group has
previously shown that perinatal administration of PCP results in an acute increase in
phosphorylated Akt levels in the hippocampus of rats4. Furthermore, activation of apoptotic
signaling cascades via Akt leads to an increase in p53 and Bax5 (also shown by the present
study), mainly regulated by MDM26,7. An immediate rise in the levels of p53 following
perinatal PCP administration would require a large recruitment of MDM2 for its
ubiquitination.
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Supplementary Methods
Immunoblotting of neuronal marker microtubule-associated protein 2 (MAP2), total Akt, and apoptotic
marker Bcl-2-associated X protein (BAX) in the hippocampus of PCP treated and control rats
Relative protein expression for MAP2, total Akt and BAX levels were determined by immunoblotting
conducted according to the protocol described in the main methods of this study; the only modification from
the protocol described in manuscript being the primary antibodies used. The primary antibodies and
concentrations used to perform these additional experiments were as follows: anti MAP2 (1:1000; M4403;
Sigma), total Akt (1:500; sc-8312; Santa Cruz) and BAX (1:500; ab7977; Abcam).

Supplementary Results
MAP2. There was a significant age x treatment interaction on MAP2 protein expression in the treated rats
(F2,29=3.87; p<0.001). Post-hoc analyses reveal that there was a 26.5% decrease in MAP2 protein expression
in the PN12 PCP treated rats compared to control rats (p=0.008; SF3). While there was no main effect of
treatment on expression levels of MAP2 (F1,29=0.07; p=0.789), there was an extremely significant age effect
on MAP2 expression levels in the hippocampus of the treated rats (F2,29=35.23; p<0.001). Post-hoc analyses
showed that MAP2 protein expression was 41% and 44% higher in the 5 week and 14 week control groups
respectively compared to the PN12 group, similarly MAP2 protein expression was increased by 57.5% and
61.5% respectively in the 5 week and 14 week PCP treated groups compared to the PN12 group
(0.001<p<0.05; SF4).
Akt. As expected, there were no significant interactions between age and treatment on total Akt levels in the
hippocampus of the treated rats (F2,30=0.24; p=0.791; SF3); nor was there a significant main effect of
treatment (F1,30=2.08; p=0.159). There was however a highly significant main effect of age on total Akt
levels (F2,30=22.03; p<0.001). Post-hoc analyses revealed that total Akt protein expression levels were 16%
and 28.5% lower in the 5 week and 14 week control age groups respectively compared to the PN12 age
group, and were 29.5% lower in the 14 week PCP treated group compared to the PN12 PCP group
(0.001<p<0.05; SF4).

Bax. There were no significant interactions between age and treatment on levels of BAX protein in the
treated rats (F2,29=1.042; p=0.366); however there was a significant effect of treatment on BAX levels in the
hippocampus (F1,29=6.706; p=0.014), with post-hoc analyses revealing that the treatment effect was
observed only in the PN12 age group, with a 26% increase in BAX protein in the hippocampus of PN12
PCP treated rats compared to controls (p=0.03; SF3). There was an extremely significant age effect in
relation to BAX protein levels in the hippocampus of the treated rats (F2,29=39.71; p<0.001). Post-hoc
analyses revealed that BAX protein levels were 29% higher in 5 week old control rats, 42% higher in 14
week old control rats compared to PN12 rats, and 19% higher in 14 week old control rats compared to 5
week old rats (0.001<p<0.01). Furthermore BAX levels were found to be 30% higher in 14 week old PCP
treated rats compared to PN12 PCP treated rats (p<0.001).

Supplementary Figures

SF1: Developmental profile of Lingo-1, NgR, p75, TROY, WNK1 and Myt1 protein expression in the hippocampus of control rats at PN12, 5 week, and 14
week time-points (n = 6 per time-point). *p<0.05, **p<0.01, and ***p<0.001.

SF2: Developmental profile of Lingo-1, NgR, p75, TROY, WNK1 and Myt1 protein expression in the hippocampus of phencyclidine-treated rats at PN12, 5
week, and 14 week time-points (n = 6 per time-point). *p<0.05, **p<0.01 and ***p<0.001.

SF3: Representative immunoblots and relative levels of MAP2, total Akt and BAX protein expression in the
hippocampus of phencyclidine (PCP) treated rats compared to controls (n = 6 per treatment per time-point).
*p<0.05, and **p<0.01.

SF4: Developmental profile of MAP2, total Akt and BAX protein expression in the hippocampus of control and phencyclidine (PCP) treated rats at PN12, 5
week, and 14 week time-points (n = 6 per treatment per time-point). *p<0.05, **p<0.01, and ***p<0.001.

